Dr Reddy’s Laboratories reported a 36% year-over-year increase in net profit for Q4, but the share price dropped 5% today. The company saw a 3% sequential decrease in net profit, and brokerages attributed the strong gross margin and operational performance to Revlimid sales. Analysts project that upcoming R&D costs and a weak US launch pipeline may impact the company’s earnings growth and EBITDA margin in the coming fiscal year.
Shares of Titan Company witnessed a significant decline of nearly 5% on the BSE today, following the release of weaker-than-expected March quarter financial results. The company’s consolidated net profit experienced a modest 5% year-on-year growth to ₹ 771 crore for the quarter ending March 31, while total income rose by 22% YoY to ₹ 11,472 crore. Despite this, the EBIT (Earnings Before Interest and Taxes) grew by a mere 10% YoY to ₹ 1,192 crore. The Jewellery segment accounted for a 19% YoY growth in quarterly income, reaching ₹ 8,998 crore, whereas the ‘Watches & Wearables’ segment generated a total income of ₹ 940 crore for the quarter.
